ClearPoint Neuro reports Q4 2023 preliminary revenue $6.8M (+32% YoY); guides FY2024 revenue $28-32M

ClearPoint Neuro, Inc.

2023-FY EPS reported -$0.90 revenue$23,955,000

Preliminary Q4 revenue $6.8M, up 32% YoY; biologics/drug delivery revenue $4.1M (+76% YoY).
Full year 2023 record revenue ~$24M (+17% YoY); biologics/drug delivery $13.6M (+49% YoY).
Cash burn ~$1.2M in Q4; cash and equivalents $23.1M at Dec 31, 2023.
FY2024 revenue guidance $28-32M (17-33% growth); expects multiple product launches including SmartFrame OR and PRISM laser.
Company plans to expand to 100 ClearPoint sites by 2025 and demonstrate operating leverage.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ClearPoint Neuro, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue approximately $6.8 million.

Period: fourth quarter and full year ended December 31, 2023
Revenue: approximately $6.8 million
Result: preliminary results

Exact text from the filing

a Form 10-K filing for the year with full financial statements. Fourth Quarter 2023 Preliminary Unaudited Financial Highlights • Preliminary unaudited revenue of approximately $6.8 million, a 32% year-over-year increase; • Increased biologics and drug delivery revenue to approximately $4.1 million, a 76% year-over-year increase; and • Cash burn of approximately

View on SEC.gov

Browse all earnings releases →

ClearPoint Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001285550-24-000016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.